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Calculation of Resistance
to Pulmonary Perfusion
In their interesting study (1) the authors report that nebulized
iloprost was more potent than inhaled nitric oxide (NO) as a
pulmonary vasodilator in patients with primary pulmonary hyper-
tension.
They conclude that iloprost caused a more intense decrease in
pulmonary vascular resistance (PVR) and a higher increase in
cardiac output (CO) than inhaled NO. However, from a hemo-
dynamic point of view, several findings reported in their study
remain to be explained. In Table 1 data for the changes in systemic
vascular resistance (SVR) and PVR in response to NO and iloprost
are listed. Not only PVR, but also SVR, significantly decreased
after iloprost.
As presented in the methods section of their paper, the
calculation of PVR and SVR was done according to the following
formulas that are widely used (2) to calculate the resistance to
pulmonary and systemic perfusion:
PVR 5
~PAPmean 2 PCWP! * 80
CO
SVR 5
~SAPmean 2 RAP) * 80
CO
As can be seen easily, any increase in cardiac output will lead to a
calculatory decrease of PVR and SVR, merely as a result of the way
these parameters are calculated (CO in the denominator). Inter-
estingly, the authors report a significant increase in CO after
iloprost nebulization (Fig. 1B, Table 1).
Any increase in CO that may result from systemic arterial
vasodilation will result in a decrease of calculated values for PVR
and SVR without any change of the tone of the pulmonary
vasculature itself. Consistent with this interpretation, the authors
clearly state that both systemic and pulmonary arterial mean
pressures decreased significantly after iloprost compared with NO
(Table 1). It would be interesting to see to what extent the ratios
of pulmonary/systemic blood pressure and the ratios of calculated
PVR/SVR changed after NO or iloprost. Only by reporting data
for the ratios of Pp/Ps and PVR/SVR specific changes in pulmo-
nary hemodynamics after exposition to a given drug can be
ascertained to be a real effect rather than representing merely a
calculatory phenomenon.
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REPLY
We appreciate Dr. Gorenflo’s interest in our manuscript. We do
not, however, share his concerns regarding the interpretation of
our results. In our study in patients with primary pulmonary
hypertension, inhaled nitric oxide caused a fall in the pulmonary
artery pressure by a mean of 7% from baseline, while the systemic
arterial pressure remained stable, clearly indicating selective pul-
monary vasodilation. Aerosolized iloprost resulted in a fall of the
pulmonary artery pressure by a mean of 13%, whereas the systemic
artery pressure declined by 3%. The mean decline in pulmonary
vascular resistance with aerosolized iloprost was 33%, and the
mean decline in systemic vascular resistance was 21%, also sug-
gesting real pulmonary vasodilation. As we stated in our manu-
script, aerosolized iloprost exerted preferential, but not selective,
pulmonary vasodilatory effects in patients with pulmonary hyper-
tension.
Whenever an increase in cardiac output is accompanied by stable
or decreased pulmonary artery pressures, there must be some
degree of pulmonary vasodilation (or recruitment of pulmonary
vessels). Back in time, when we used to test oral calcium channel
blockers in almost every patient with primary pulmonary hyper-
tension (1), we observed several patients in whom the systemic
arterial pressure decreased, the cardiac output increased and the
pulmonary artery pressure also increased. In these patients, the
pulmonary vascular resistance remained constant. This is what
happens when there is systemic vasodilation accompanied by
reflectory increase in cardiac output but lack of pulmonary vaso-
dilation.
Marius M. Hoeper, MD
Department of Pulmonary Medicine
Hannover Medical School
30623 Hannover, Germany
PII S0735-1097(00)00883-4
REFERENCE
1. Hoeper MM, Wilke T, Welte T, Breuer HWM, Wagner TOF. How
effective is the treatment with high-dose nifedipine for primary pulmo-
nary hypertension? Sem Respir Crit Care Med 1994;15:490–4.
1440 Letters to the Editor JACC Vol. 36, No. 4, 2000
October 2000:1432–40
